Sunday, August 23, 2009
Stemedica Requests Pre-IND Meeting With FDA
¶ 5:20 AM
Stemedica Cell Technologies, Inc. USA, a leader in adult stem radiophone research and manufacturing, has requested a pre-Investigational New Drug (IND) meeting with the U.S. Food and Drug Administration ("FDA") to discuss a proposed IND to use Stemedica's proprietary line of allogeneic mesenchymal bone marrow cells (adult human) as a treatment for ischemic stroke. (PRWeb Aug 21, 2009)
Read the full story at http://www.prweb.com/releases/Stemedica-Stroke/PRE-IND-FDA/prweb2776804.htm
¶ 5:20 AM